Advertisement
Original Study| Volume 21, ISSUE 8, P1086-1092.e1, August 2020

Drug Burden Index and Cognitive and Physical Function in Aged Care Residents: A Longitudinal Study

      Abstract

      Objectives

      Anticholinergic/antimuscarinic and sedative medications (eg, benzodiazepines) have been found to be associated with poorer cognitive and physical function and mobility impairment in older age. However, previous studies were mostly conducted among community-dwelling older individuals and had often a cross-sectional design. Accordingly, our aim was to examine longitudinal associations between cumulative exposure to anticholinergic and sedative medications and cognitive and physical function among residents from aged care homes.

      Design

      Longitudinal study.

      Setting and Participants

      A total of 4624 residents of Dutch aged care homes of whom data were collected between June 2005 and April 2014.

      Methods

      Outcome measures were collected with the Long-Term Care Facilities assessment from the international Residential Assessment Instrument (interRAI-LTCF) and included the Cognitive Performance Scale, the Activities of Daily Living (ADL) Hierarchy scale, a timed 4-meter walk test, distance walked, hours of physical activity, and days being outside. Cumulative exposure to anticholinergic and sedative medications was calculated with the Drug Burden Index (DBI), a linear additive pharmacological dose-response model. Associations were examined with linear mixed models to take the potential dependence of observations into account (ie, data were collected at repeated assessment occasions of residents who were clustered in aged care homes). Analyses were adjusted for sex, age, dementia, comorbidity (neurological, psychiatric, cardiovascular, oncological, and pulmonary), fractures, depressive symptoms, and medications excluded from the DBI.

      Results

      We observed significant longitudinal associations between a higher DBI and poorer ADLs, fewer hours of physical activity, and fewer days being outside. We found no significant longitudinal association between a higher DBI and poorer cognitive function.

      Conclusions and Implications

      Over time, cumulative exposure to anticholinergic and sedative medications is associated with poorer physical but not cognitive function in aged care residents. Careful monitoring of aged care residents with high cumulative anticholinergic and sedative medication exposure is needed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Richardson K.
        • Bennett K.
        • Kenny R.A.
        Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults.
        Age Ageing. 2015; 44: 90-96
        • Chatterjee S.
        • Bali V.
        • Carnahan R.M.
        • et al.
        Anticholinergic medication use and risk of fracture in elderly adults with depression.
        J Am Geriatr Soc. 2016; 64: 1492-1497
        • Fox C.
        • Smith T.
        • Maidment I.
        • et al.
        Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: A systematic review.
        Age Ageing. 2014; 43: 604-615
        • Pasina L.
        • Djade C.D.
        • Lucca U.
        • et al.
        Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: Comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: Results from the REPOSI study.
        Drugs Aging. 2013; 30: 103-112
        • Gray S.L.
        • Penninx B.W.
        • Blough D.K.
        • et al.
        Benzodiazepine use and physical performance in community-dwelling older women.
        J Am Geriatr Soc. 2003; 51: 1563-1570
        • Landi F.
        • Russo A.
        • Liperoti R.
        • et al.
        Anticholinergic drugs and physical function among frail elderly population.
        Clin Pharmacol Ther. 2007; 81: 235-241
        • Mulsant B.H.
        • Pollock B.G.
        • Kirshner M.
        • et al.
        Serum anticholinergic activity in a community-based sample of older adults: Relationship with cognitive performance.
        Arch Gen Psychiatry. 2003; 60: 198-203
        • Koyama A.
        • Steinman M.
        • Ensrud K.
        • et al.
        Long-term cognitive and functional effects of potentially inappropriate medications in older women.
        J Gerontol A Biol Sci Med Sci. 2014; 69: 423-429
        • Ancelin M.L.
        • Artero S.
        • Portet F.
        • et al.
        Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study.
        BMJ. 2006; 332: 455-459
        • Hilmer S.N.
        • Mager D.E.
        • Simonsick E.M.
        • et al.
        A drug burden index to define the functional burden of medications in older people.
        Arch Intern Med. 2007; 167: 781-787
        • Kouladjian L.
        • Gnjidic D.
        • Chen T.F.
        • et al.
        Drug burden index in older adults: Theoretical and practical issues.
        Clin Interv Aging. 2014; 9: 1503-1515
        • Wouters H.
        • van der Meer H.
        • Taxis K.
        Quantification of anticholinergic and sedative drug load with the drug burden index: A review of outcomes and methodological quality of studies.
        Eur J Clin Pharmacol. 2017; 23: 257-266
        • Wilson N.M.
        • Hilmer S.N.
        • March L.M.
        • et al.
        Associations between drug burden index and falls in older people in residential aged care.
        J Am Geriatr Soc. 2011; 59: 875-880
        • Bosboom P.R.
        • Alfonso H.
        • Almeida O.P.
        • Beer C.
        Use of potentially harmful medications and health-related quality of life among people with dementia living in residential aged care facilities.
        Dement Geriatr Cogn Dis Extra. 2012; 2: 361-371
        • Wilson N.M.
        • Hilmer S.N.
        • March L.M.
        • et al.
        Associations between drug burden index and physical function in older people in residential aged care facilities.
        Age Ageing. 2010; 39: 503-507
        • Wilson N.M.
        • Hilmer S.N.
        • March L.M.
        • et al.
        Associations between drug burden index and mortality in older people in residential aged care facilities.
        Drugs Aging. 2012; 29: 157-165
        • Haasum Y.
        • Fastbom J.
        • Johnell K.
        Institutionalization as a risk factor for inappropriate drug use in the elderly: A Swedish nationwide register-based study.
        Ann Pharmacother. 2012; 46: 339-346
        • WHO Collaborating Centre for Drug Statistics Methodology
        Anatomical therapeutic chemical (ATC) classification index. 2019.
        (Available at:) (Accessed July 20, 2020)
        • The Royal Dutch Association of Pharmacists (KNMP)
        Compendium of drug information.
        Drug Information Center, The Hague2017
        • Morris J.N.
        • Fries B.E.
        • Mehr D.R.
        • et al.
        MDS cognitive performance scale.
        J Gerontol. 1994; 49: M174-M182
        • Morris J.N.
        • Fries B.E.
        • Morris S.A.
        Scaling ADLs within the MDS.
        J Gerontol A Biol Sci Med Sci. 1999; 54: M546-M553
        • Poss J.W.
        • Jutan N.M.
        • Hirdes J.P.
        • et al.
        A review of evidence on the reliability and validity of minimum data set data.
        Healthc Manage Forum. 2008; 21: 33-39
        • Onder G.
        • Carpenter I.
        • Finne-Soveri H.
        • et al.
        Assessment of nursing home residents in Europe: The services and health for elderly in long TERm care (SHELTER) study.
        BMC Health Serv Res. 2012; 12: 5
        • Burrows A.B.
        • Morris J.N.
        • Simon S.E.
        • et al.
        Development of a minimum data set-based depression rating scale for use in nursing homes.
        Age Ageing. 2000; 29: 165-172
        • Halvorsen K.H.
        • Granas A.G.
        • Engeland A.
        • Ruths S.
        Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs.
        Pharmacoepidemiol Drug Saf. 2012; 21: 929-936
        • Morris J.N.
        • Howard E.P.
        • Steel K.
        • et al.
        Updating the cognitive performance scale.
        J Geriatr Psychiatry Neurol. 2016; 29: 47-55
        • Cardwell K.
        • Hughes C.M.
        • Ryan C.
        The association between anticholinergic medication burden and health related outcomes in the ‘oldest old': A systematic review of the literature.
        Drugs Aging. 2015; 32: 835-848
        • Pont L.G.
        • Nielen J.T.
        • McLachlan A.J.
        • et al.
        Measuring anticholinergic drug exposure in older community-dwelling Australian men: A comparison of four different measures.
        Br J Clin Pharmacol. 2015; 80: 1169-1175
        • Wouters H.
        • Scheper J.
        • Koning H.
        • et al.
        Discontinuing inappropriate medication use in nursing home residents: A cluster randomized controlled trial.
        Ann Intern Med. 2017; 167: 609-617
        • Ballard C.
        • Lana M.M.
        • Theodoulou M.
        • et al.
        A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
        PLoS Med. 2008; 5: e76
        • Patterson S.M.
        • Hughes C.M.
        • Crealey G.
        • et al.
        An evaluation of an adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in northern Ireland (Fleetwood Northern Ireland Study).
        J Am Geriatr Soc. 2010; 58: 44-53